Abstract:Aims/hypothesis: Immunotherapeutics targeting T cells are crucial for inhibiting autoimmune disease progression proximal to disease onset in type 1 diabetes. A growing number of T cell-directed therapeutics have demonstrated partial therapeutic efficacy, with anti-CD3 (α-CD3) representing the only regulatory agency-approved drug capable of slowing disease progression through a mechanism involving the induction of partial T cell exhaustion. There is an outstanding need to augment the durability and effectiveness of T cell targeting by directly restraining proinflammatory T helper type 1 (Th1) and type 1 cytotoxic CD8+ T cell (Tc1) subsets, while simultaneously augmenting regulatory T cell (Treg) activity. Here, we present a novel strategy for reducing diabetes incidence in the NOD mouse model using a blocking monoclonal antibody targeting the type 1 diabetes-risk associated T cell co-stimulatory receptor, CD226. Methods: Female NOD mice were treated with anti-CD226 between 7-8 weeks of age and then monitored for diabetes incidence and therapeutic mechanism of action. Results: Compared to isotype-treated controls, anti-CD226 treated NOD mice showed reduced insulitis severity at 12 weeks and decreased disease incidence at 30 weeks. Flow cytometric analysis performed five weeks post-treatment demonstrated reduced proliferation of CD4+ and CD8+ effector memory T cells in spleens of anti-CD226 treated mice. Phenotyping of pancreatic Tregs revealed increased CD25 expression and STAT5 phosphorylation following anti-CD226, with splenic Tregs displaying augmented suppression of CD4+ T cell responders in vitro. Anti-CD226 treated mice exhibited reduced frequencies of islet-specific glucose-6-phosphatase catalytic subunit related protein (IGRP)-reactive CD8+ T cells in the pancreas, using both ex vivo tetramer staining and single-cell T cell receptor sequencing (scTCR-seq) approaches. 51Cr-release assays demonstrated reduced cell-mediated lysis of beta-cells by anti-CD226-treated autoreactive cytotoxic T lymphocytes. Conclusions/interpretation: CD226 blockade reduces T cell cytotoxicity and improves Treg function, representing a targeted and rational approach for restoring immune regulation in type 1 diabetes.

Induced Regulatory T Cells Suppress Tc1 Cells Through TGF-β Signaling to Ameliorate STZ-induced Type 1 Diabetes Mellitus

Ginsenoside Rg1 Improves Inflammation and Autophagy of the Pancreas and Spleen in Streptozotocin-Induced Type 1 Diabetic Mice.

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes

Alteration of Regulatory T Cells in Type 1 Diabetes Mellitus: A Comprehensive Review

Tolerogenic Vaccination Reduced Effector Memory Cd4 T Cells and Induced Effector Memory Treg Cells for Type I Diabetes Treatment

Regulatory T Cells and Type 1 Diabetes

Intestinal Type 1 Regulatory T Cells Migrate to Periphery to Suppress Diabetogenic T Cells and Prevent Diabetes Development

Complement C3 Deficiency Prevent Against the Onset of Streptozotocin-Induced Autoimmune Diabetes Involving Expansion of Regulatory T Cells

Type-1 interferon induced cross-regulation of IL-10 function: a novel mechanism in type 1 diabetes development

Tolerogenic Vaccine Composited with Islet Derived Multipeptides and Cyclosporin A Induces pTreg and Prevents Type 1 Diabetes in Murine Model.

Diabetes is Not Prevented by Foxp3-Transduced Cd4(+)T Cells under the Il-12r Beta 2 Promoter Control

Beyond Knockout: A Novel Homodimerization-Targeting MyD88 Inhibitor Prevents and Cures Type 1 Diabetes in NOD Mice

CXCL12-CXCR4 Mediates CD57+ CD8+ T Cell Responses in the Progression of Type 1 Diabetes.

Regulatory CD4+ T cells redirected against pathogenic CD8+ T cells protect NOD mice from development of autoimmune diabetes

Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function

Recombinant Ling Zhi-8 Enhances Tregs Function to Restore Glycemic Control in Streptozocin-Induced Diabetic Rats

Systemic Transforming Growth Factor-??1 Gene Therapy Induces Foxp3+ Regulatory Cells, Restores Self-Tolerance, and Facilitates Regeneration of Beta Cell Function in Overtly Diabetic Nonobese Diabetic Mice

Umbilical cord blood and peripheral blood-derived regulatory T cells therapy: Progress in type 1 diabetes

NAG-1/GDF15 protects against streptozotocin-induced type 1 diabetes by inhibiting apoptosis, preserving beta-cell function, and suppressing inflammation in pancreatic islets